Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Genentech, Inc.

Yumanity Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Black Diamond Therapeutics, Inc.

Matthew C Lucas

Andrew William Thomas

Roland Jakob-Roetne

Bernd Buettelmann

Ryan Craig Schoenfeld

Johannes Cornelius Hermann

Fernando Padilla

Zachary Kevin Sweeney

Henner Knust

Robert James Weikert

Daniel P Sutherlin

Brian Salvatore Safina

Georgette M Castanedo

Joshua Jahmil Kennedy-Smith

Bryan K Chan

Shaoqing Chen

Clara Jeou Jen Lin

Stephen Colin Price

Eileen Mary Seward

Michael Soth

Bertrand Le Bourdonnec

Stephen Matthew Lynch

Matthew Michael Hamilton

Achyutharao Sidduri

Francisco Xavier Talamas

Kin-Chun Thomas Luk

Peter Michael Wovkulich

Sharada Shenvi Labadie

Ann Marie Madera

Bhaumik Pandya

Kenneth Rhodes

Stephen Deems Gabriel

Yan Lou

Yimin Qian

Ce Wang

Javier De Vicente Fidalgo

Timothy D Owens

Fariborz Firooznia

Allen John Lovey

Keshab Sarma

Paul Spurr

Hongju Li

Pius Waldmeier

David Scott Carter

Parcharee Tivitmahaisoon

Steven Joseph Berthel

Pravin Iyer

Jutta Wanner

Xiaohu Zhang

Andreas Kuglstatter

Daniel Tardiff

Pascal Pierre Alexandre Savy

David Goldstein

Rama Kondru

Wylie Palmer

Robert Scannevin

Maria-Clemencia Hernandez

Nidhi Arora

Amy Geraldine Moore

Yansheng Zhai

Eva Papp

Niala Bhagirath

Luca Arista

Elizabeth Buck

Kerem Ozboya

Joshua Kennedy-Smith

Rebecca Aron

Jeff Piotrowski

Marzia Villa

Kerem Erol Ozboya

Nam T Le

Clara Jeou Lin

Iwona Wrona

Joshua Paul Gergely Taygerly

Benjamin Vincent

Steven Paul Hanlon

Eric Solis

Chee-Yeun Chung

Alexander Flohr

Daniel Fishlock

Wenwei Xie

Lee Edwin Lowrie, Jr

Counde O'yang

Jun-Bae Hong

Steven Berthel

Roetne Roland Jakob

Jr Lee Edwin Lowrie

Thimothy D Owens

Stephen M Lynch

The present disclosure relates to compounds of Formula (I′): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Alkynyl quinazoline compounds

The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression. Patients that may be treated using the compositions and methods described herein include those that express a mutant TDP-43 isoform containing a mutation associated with TDP-43-promoted aggregation and toxicity.

Compositions and methods for the treatment and prevention of neurological disorders

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Methods for the treatment of neurological disorders

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Compounds and uses thereof

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases. 

Inhibitors of SYK

Compounds of the formula I or II: wherein X, m, Ar, Rand Rare as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

The present invention relates to the use of novel compounds of formula (I), wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases. 

1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK

The present invention relates to the use of novel compounds of Formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Thienopyrimidine compounds

The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases. 

Pyrrolo[2,3-B]pyrazines as SYK inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.

N-alkyltriazole compounds as LPAR antagonists

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Imidazopyridazine compounds

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, Rto Rare as described herein. The compounds are active on the GABA A &#x3b1;5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

Isoxazolo-pyridine derivatives

The present invention relates to the use of novel thiazolopyrimidine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Thiazolopyrimidine compounds

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Pyridazine amide compounds useful as SYK inhibitors

Growing community of inventors

Verona, NJ, United States of America

Matthew C Lucas